Product Code: SR112025A2205
The global isothermal nucleic acid amplification technology market size was valued at USD 3.4 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 8.2 Billion by 2033, exhibiting a CAGR of 10.3% during 2025-2033. North America currently dominates the market, holding a market share of over 43.4% in 2024. The rising demand for fast and accurate diagnostics, increasing prevalence of infectious diseases, rapid advancements in portable testing devices, and expanding applications across healthcare, food safety, and environmental monitoring, with strong support from government initiatives are major factors boosting the isothermal nucleic acid amplification technology market share.
The isothermal nucleic acid amplification technology (INAAT) is used in molecular biology and recombinant DNA technologies for detecting and identifying nucleic acids. It is commonly used to amplify nucleic acids at a constant temperature, thereby eliminating the need for thermocycler equipment. It is majorly utilized for RNA, DNA, cells, proteins, small molecules, and ions to ensure the rapid, sensitive and accurate diagnosis of genetic, inherited, and infectious diseases. It generates amplicons that are employed in producing versatile nucleic acid nanomaterials. Besides this, it assists in detecting various infectious diseases, such as (HIV), tuberculosis, influenza, hepatitis A and B, chlamydia, and gonorrhea (CT/NG). As a result, INAAT is gaining immense traction across the globe.
Global Isothermal Nucleic Acid Amplification Technology Market Trends:
The ongoing development in INAAT for detecting coronavirus disease (COVID-19) represents one of the key factors positively influencing the market. In line with this, the increasing geriatric population globally and the rising prevalence of cancer and other chronic medical disorders, along with the escalating demand for efficient diagnosis and treatment alternatives, are contributing to the market growth. Apart from this, the adoption of loop-mediated isothermal amplification (LAMP) tests to amplify DNA and RNA and the identification of genetically modified organisms (GMOs) is catalyzing the demand for INAAT. Furthermore, the development of strand displacement amplification (SDA), single primer isothermal amplification (SPIA), and recombinase polymerase amplification (RPA) are acting as another growth-inducing factor. Moreover, increasing investments in research and development (R&D) activities by leading market players are projected to drive the market.
Key Market Segmentation:
Breakup by Product:
Reagents hold the majority of the global isothermal nucleic acid amplification technology market share due to their increasing use in therapeutics.
Breakup by Technology:
- Helicase-Dependent Amplification (HDA)
- Nicking Enzyme Amplification Reaction (NEAR)
- Loop-Mediated Isothermal Amplification (LAMP)
- Strand Displacement Amplification (SDA)
- Nucleic Acid Sequence-Based Amplification (NASBA)
- Transcription Mediated Amplification (TMA)
- Single Primer Isothermal Amplification (SPIA)
- Others
TMA accounts for the majority of the total market share as it allows a clinical laboratory to perform nucleic acid test (NAT) assays for blood screening with fewer steps and less processing time.
Breakup by Application:
- Infectious Disease Diagnosis
- Hepatitis
- CT/NG
- HIV
- Influenza
- Others
- Blood Screening
- Others
Infectious disease diagnosis currently dominates the market due to the rising prevalence of infectious diseases across the globe.
Breakup by End-User:
- Hospitals
- Diagnostic Laboratories
- Research Laboratories
- Others
Hospitals presently dominate the market due to the increasing number of hospitals and significant development in the healthcare industry.
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America exhibits a clear dominance in the market due to the shifting consumer preference for INAAT testing over traditional diagnostic procedures.
Competitive Landscape:
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Abbott Laboratories, bioMerieux SA, Becton, Dickinson and Company, Eiken Chemical Co. Ltd., Hologic Inc., Meridian Bioscience Inc., OptiGene Limited, Thermo Fisher Scientific Inc., Tecan Trading AG, and Ustar Biotechnologies Ltd.
Key Questions Answered in This Report
- 1.How big is the isothermal nucleic acid amplification technology market?
- 2.What is the future outlook of isothermal nucleic acid amplification technology market?
- 3.What are the key factors driving the isothermal nucleic acid amplification technology market?
- 4.Which region accounts for the largest isothermal nucleic acid amplification technology market share?
- 5.Which are the leading companies in the global isothermal nucleic acid amplification technology market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Isothermal Nucleic Acid Amplification Technology Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of Covid-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Instruments
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Reagents
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Technology
- 7.1 Helicase-Dependent Amplification (HDA)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Nicking Enzyme Amplification Reaction (NEAR)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Loop-Mediated Isothermal Amplification (LAMP)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Strand Displacement Amplification (SDA)
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Nucleic Acid Sequence-Based Amplification (NASBA)
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Transcription Mediated Amplification (TMA)
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
- 7.7 Single Primer Isothermal Amplification (SPIA)
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
- 7.8 Others
- 7.8.1 Market Trends
- 7.8.2 Market Forecast
8 Market Breakup by Application
- 8.1 Infectious Disease Diagnosis
- 8.1.1 Market Trends
- 8.1.2 Major Types
- 8.1.2.1 Hepatitis
- 8.1.2.2 CT/NG
- 8.1.2.3 HIV
- 8.1.2.4 Influenza
- 8.1.2.5 Others
- 8.1.3 Market Forecast
- 8.2 Blood Screening
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by End-User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Diagnostic Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Research Laboratories
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 bioMerieux
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 BD (Becton, Dickinson and Company)
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Eiken Chemical Co. Ltd
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 Hologic Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Meridian Bioscience Inc.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 OptiGene Limited
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.8 Thermo Fisher Scientific Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Tecan Trading AG
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 Ustar Biotechnologies Ltd.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio